Hualan Biological Bacterin Inc.
301207.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.83B
Close$
$9.60
49.8% downside
Current Fair Value
49.8% downsideOvervalued by 49.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.83 Billion |
|---|---|
| Enterprise Value | $11.48 Billion |
| Dividend Yield | $1.40 (7.04%) |
| Earnings per Share | $0.31 |
| Beta | 0.6 |
| Outstanding Shares | 595,000,033 |
Return
| Return on Equity | 3.77% |
|---|---|
| Return on Assets | 3.16% |
| Return on Invested Capital | 3.61% |
Valuation & Multiples
| P/E Ratio | 59.11 |
|---|---|
| PEG | -64.05 |
| Price to Sales | 19.12 |
| Price to Book Ratio | 2.39 |
| Enterprise Value to Revenue | 9.67 |
| Enterprise Value to EBIT | 59.98 |
| Enterprise Value to Net Income | 57 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 29, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hualan Biological Bacterin Inc.
708 employees
CEO: Wenjue An Hualan Biological Bacterin Inc. is a Chinese pharmaceutical company focused on the entire vaccine lifecycle, from research and development to manufacturing and sales within China. The company's product line features a diverse range of im...